Patents by Inventor Michael THOMENIUS

Michael THOMENIUS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF EZH2 INHIBITORS FOR TREATING CANCER
    Publication number: 20240139203
    Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.
    Type: Application
    Filed: September 6, 2023
    Publication date: May 2, 2024
    Inventors: Scott RIBICH, Michael THOMENIUS
  • Methods of treating cancer by inhibiting SETD2
    Patent number: 11952572
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 9, 2024
    Assignee: Epizyme, Inc.
    Inventors: Alexandra Rose Grassian, Michael Thomenius, Jennifer Anne Totman
  • Use of EZH2 inhibitors for treating cancer
    Patent number: 11786533
    Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 17, 2023
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • SUBSTITUTED INDOLES AND METHODS OF USE THEREOF
    Publication number: 20230075198
    Abstract: The present disclosure provides substituted indole compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.
    Type: Application
    Filed: August 14, 2019
    Publication date: March 9, 2023
    Inventors: John LAMPE, John CAMPBELL, Kenneth DUNCAN, Megan Alene Cloonan FOLEY, Darren Martin HARVEY, Michael John MUNCHHOF, Michael THOMENIUS, Lawrence Alan REITER
  • METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2
    Publication number: 20230049113
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
    Type: Application
    Filed: November 26, 2019
    Publication date: February 16, 2023
    Inventors: Michael THOMENIUS, Katherine Louise COSMOPOULOS, Jennifer Anne TOTMAN
  • USE OF EZH2 INHIBITORS FOR TREATING CANCER
    Publication number: 20220288085
    Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 15, 2022
    Inventors: Scott RIBICH, Michael THOMENIUS
  • EZH2 INHIBITORS FOR TREATING CANCER
    Publication number: 20220105098
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: September 14, 2021
    Publication date: April 7, 2022
    Inventors: Scott RIBICH, Michael THOMENIUS
  • EZH2 inhibitors for treating cancer
    Patent number: 11147819
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 19, 2021
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • Methods Of Treating Cancer By Inhibiting SETD2
    Publication number: 20210002645
    Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
    Type: Application
    Filed: August 14, 2018
    Publication date: January 7, 2021
    Inventors: Alexandra Rose Grassian, Michael THOMENIUS, Jennifer Anne TOTMAN
  • EZH2 INHIBITORS FOR TREATING CANCER
    Publication number: 20190328743
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 31, 2019
    Inventors: Scott RIBICH, Michael THOMENIUS